Research & Development

Engaging Biopharma and Government to Combat Resurgent Mpox
Research & Development Engaging Biopharma and Government to Combat Resurgent Mpox

Mpox has made a concerning comeback, compelling immediate and collaborative action. With an increased threat from the Clade Ib strain, the situation demands an effective response framework modeled after successful strategies used in the COVID-19 pandemic. This involves substantial input from both

How Will FDA's sIRB Mandate Transform Multisite Clinical Trials?
Research & Development How Will FDA's sIRB Mandate Transform Multisite Clinical Trials?

The clinical research landscape is on the cusp of a transformative shift with the U.S. Food and Drug Administration (FDA) poised to implement a groundbreaking regulation by May 2025. This regulation mandates the use of a single, centralized institutional review board (sIRB) for multisite trials,

Opposition Leader Urges Faster Vaccine Production at Dei BioPharma Inspection
Research & Development Opposition Leader Urges Faster Vaccine Production at Dei BioPharma Inspection

Uganda’s Leader of Opposition, Joel Ssenyonyi, alongside a group of 15 other Members of Parliament, recently conducted an insightful inspection of the Dei BioPharma facility located in Matugga. This visit, which took place on September 19, 2024, marked a significant milestone that underscored the f

Kaida BioPharma Enhances Social Media Presence to Combat Cancer
Research & Development Kaida BioPharma Enhances Social Media Presence to Combat Cancer

Kaida BioPharma, an emerging pharmaceutical company based in Fort Lauderdale, Florida, has announced the launch of its new corporate social media channels. This significant development aims to enhance the company’s presence across various platforms, including X, LinkedIn, and Facebook. By l

FDA Approves Kisqali Expanding Breast Cancer Treatment Options Over Verzenio
Research & Development FDA Approves Kisqali Expanding Breast Cancer Treatment Options Over Verzenio

In a significant move likely to reshape the competitive landscape, the FDA has granted approval for Novartis’ Kisqali, when paired with an aromatase inhibitor, for the adjuvant treatment of HR-positive, HER2-negative stage 2 and 3 breast cancer at high risk of recurrence post-surgery. This approval

Can GC Therapeutics' TFome Platform Revolutionize Cell Therapy?
Research & Development Can GC Therapeutics' TFome Platform Revolutionize Cell Therapy?

GC Therapeutics (GCTx), a biotech company founded in 2019, has captured the spotlight with its pioneering approach to cell therapy. With a mission centered on advanced induced pluripotent stem cell (iPSC)-based medicines, GCTx is driven by its innovative TFome platform. Bolstered by a successful

Loading

Subscribe to our weekly news digest.

Join now and become a part of our fast-growing community.

Invalid Email Address
Thanks for Subscribing!
We'll be sending you our best soon!
Something went wrong, please try again later